Being Principal Investigators on Pharma-initiated Clinical Trials: Have we Sold Ourselves Too Cheap?

Journal Title: UNKNOWN - Year 2017, Vol 7, Issue 1

Abstract

The other day in clinic I was going through one of those good-clinical-practice (GCP) modules, as requested by one of the pharma companies in order for me to participate as an investigator in one of their clinical trial. As I repetitively wasn't able to correctly answer the minimum 80% of the questions needed for me to pass the final test of the module, my morning hours just flew by, and with my increasing level of anxiety, it suddenly dawned on me-we, physician-investigators participating in pharma-initiated clinical trials, have sold ourselves too cheap.

Authors and Affiliations

Leibowitz-Amit R

Keywords

Related Articles

Efficacy and Tolerance of an Injectable Medical Device Containing Hyaluronic Acid and Amino acids: A Monocentric Six-Month Open-Label Evaluation

Background: An innovative injectable solution containing low molecular hyaluronic acid (HA) and a specific Amino Acids mixture was formulated to physiologically promote local neo-collagenesis and elastogenesis through fi...

Toward a Comprehensive and Accurate Measure of Clinical Trial Workload, Equity, Quality Assurance and Patient Safety-How Much Workload is Too Much? Commentary and Brief Research Report

This article provides a brief commentary on the methodology surrounding controlled clinical trials, the growing trend of centers conducting multiple controlled trials (i.e. “factory science”), trial workload measures, an...

Effect of Deep Brain Stimulation of the Globus Pallidus Internus on Quality of Life in Young Patients with Dyskinetic Cerebral Palsy (STIM-CP): a Prospective Single-Arm Multicenter Trial with a Double-Blind Cross-Over at 12-Months Follow-up

Introduction: Deep brain stimulation of the globus pallidus internus (GPi-DBS) can be effective in patients with dyskinetic cerebral palsy (CP), but outcome in terms of dystonia severity is often less pronounced and more...

Hierarchical Agglomerative Cluster Analysis as a Trial Method Revealing Developmental Coordination Disorder (DCD) Subtypes

Background: There is increasing evidence that children with DCD have been classified into distinguishable ‘subtypes’ mainly based on perceptual-motor, fine and gross motor skills. Previous research efforts define and des...

Myocardial Ischemia and Infarction Related to the Highly Sensitive Cardiac Troponin after Noncardiac Surgery: A Review

Although Acute Myocardial Infarct (AMI) from its classic symptomatology added or not to electrocardiographic changes is a significant cause of perioperative associated mortality, when it is only plotted from the enzymati...

Download PDF file
  • EP ID EP382344
  • DOI 10.4172/2167-0870.1000295
  • Views 41
  • Downloads 0

How To Cite

Leibowitz-Amit R (2017). Being Principal Investigators on Pharma-initiated Clinical Trials: Have we Sold Ourselves Too Cheap?. UNKNOWN, 7(1), 1-2. https://europub.co.uk/articles/-A-382344